Developer docs
API playgroundTry for free, no card

Search company profiles

Celularity

Full company profile

uuid00009p7

Namestring
Celularity
Legal namestring
Celularity Inc.
Websiteurl
celularity.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Celularity Inc. (NASDAQ: CELU) is a clinical-stage regenerative and cellular medicine company developing and commercializing off-the-shelf, cryopreserved, allogeneic cell therapies and advanced biomaterial products derived from the postpartum placenta, targeting age-related and degenerative diseases. Its core scientific platform, the Celularity IMPACT™ (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) system, operates from a 150,000 sq ft FDA-compliant cGMP facility in Florham Park, NJ, with nine Grade C/ISO-7 suites, six Grade D/ISO-8 labs, and 100+ specialized scientists. The pipeline includes placental-derived natural killer cell therapies (CYNK-001 and genetically-modified CYNK-101 with IND clearance for glioblastoma), allogeneic placental CAR-T cells with TCR knockout (CyCART), mesenchymal-like adherent stromal cells (PDA-001/PDA-002, marketed as cenplacel-L for physician-directed investigational use in Florida), and preclinical placental exosomes (pEXO); the wholly-owned Lifebank/LifebankUSA subsidiary provides private cellular banking subscription services for cord blood, cord tissue, and placental tissue.

Celularity's revenue model historically combined direct sales of biomaterial products (Biovance, Interfyl, CentaFlex, REBOUND, NATALIN, Biovance 3L Ocular) to wound care and orthopedic specialists, Lifebank subscription services, and CDMO offerings, with the biomaterials franchise out-licensed to NexGel in April 2026 for $13.3M upfront and up to $20.0M in milestones/royalties, leaving Celularity with exclusive manufacturing revenue from NexGel plus cenplacel-L commercialization via Fountain Life in Florida under Florida Statutes §458.3245 and §459.0127. Go-to-market motions are multi-pronged: enterprise field sales for physician access, channel partnerships for state-level investigational use, direct-to-consumer for Lifebank banking subscriptions, and OEM/licensing for the biomaterials franchise now handled by NexGel. Founded in 2017 as a spin-out from Celgene (tracing back to Anthrogenesis founded in 1998), Celularity became publicly traded on NASDAQ in 2021 and is led by Founder/Chairperson/CEO Robert J. Hariri, M.D., Ph.D., with recent additions including CCO Rick Gonzalez (May 2026) and Acting CFO John Sprague (February 2026).

Short descriptiontext

Celularity Inc. is a clinical-stage regenerative medicine company developing off-the-shelf placental-derived allogeneic cell therapies (cenplacel-L, CYNK-001, CYNK-101, CyCART) and operating the Lifebank cellular banking subscription service, targeting age-related and degenerative diseases through its Florham Park, NJ cGMP manufacturing platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFlorham Park, United States
HQ citystring
Florham Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
regenerative medicine, allogeneic cell therapy, placental-derived biologics, cellular medicine manufacturing, cord tissue banking
Industry3 codes
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAGAMAE
Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Blood and Organ Banks621991
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Regenerative Cell Therapy
Social media profiles3 records
GTM motion6 records

Each record includes

Type, Description, Source

Revenue model6 records
1Advanced biomaterial product sales
TypeHardware Sales
Description

Commercial sales of placental-derived biomaterial products including Biovance, Biovance 3L, Interfyl, CentaFlex, Natalin, REBOUND and Biovance 3L Ocular used in wound care, orthopedics, ocular surface reconstruction and surgical tendon management. Portfolio largely out-licensed to NexGel as of April 2026 with milestone payments and royalties, and Celularity retained exclusive manufacturing rights at its Florham Park facility.

celularity.com
2Cenplacel-L cell therapy sales
TypeHardware Sales
Description

Commercial sales of cenplacel-L (placental-derived allogeneic investigational cell therapy, also known as PDA-001/PDA-002) to licensed physicians in permissive regulatory markets starting in Florida under Florida Statutes § 458.3245 and § 459.0127, via Fountain Life channel; therapy has not received FDA approval for any indication.

celularity.com
3Lifebank cellular banking subscription services
TypeSubscription Recurring
Description

Private cellular banking subscription services for expectant parents and adults banking cord tissue, placental tissue and other cellular material via LifebankUSA platform; recurring consumer subscription revenue with over 20 years of operating history under predecessor brand.

celularity.com
4Contract Development and Manufacturing Organization (CDMO) services
TypeProfessional Services
Description

CDMO services for strategic partners using Celularity's integrated GMP manufacturing platform, supporting both internal programs and external customers in cell therapy and biomaterial production.

celularity.com
5Licensing royalties and milestone payments (NexGel transaction)
TypeLicensing Royalties
Description

Up to $20.0 million in future milestone payments based on net sales thresholds and royalties on net sales of certain development-stage products licensed to NexGel as part of biomaterials portfolio transaction closed April 21, 2026.

celularity.com
6Exclusive manufacturing revenue from NexGel
TypeManaged Services
Description

Ongoing manufacturing revenue stream from acting as exclusive manufacturer for NexGel-licensed biomaterial products at FDA-compliant Florham Park, NJ facility.

celularity.com
Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Lifebank private cellular banking subscription for expectant parents and adults
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing not publicly disclosed; includes cord tissue, placental tissue and other cellular material banking options

celularity.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1Lifebank (LifebankUSA)
Description

Private cellular and tissue biobanking service offering cord blood, cord tissue, and placental tissue preservation for families, operating since 1998.

celularity.com
+12 more records
Core offering1 text field

Celularity develops and commercializes off-the-shelf, allogeneic, cryopreserved cell therapies and advanced biomaterial products derived from postpartum human placenta, including placental Natural Killer cell therapies (CYNK-001, CYNK-101), placental CAR-T cells (CyCART), placental mesenchymal-like adherent stromal cells (PDA-001/PDA-002 / cenplacel-L) and placental exosomes. The company also sells advanced biomaterial allografts (Biovance, Interfyl, CentaFlex, NATALIN, REBOUND, Acelagraft) and operates the LifebankUSA private cellular banking subscription service, with manufacturing performed at a 150,000 sq ft FDA-registered cGMP facility in Florham Park, NJ.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Celularity operates a platform-plus-modules architecture anchored by its Celularity IMPACT™ fully integrated placental-derived cell therapy manufacturing platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) located at a 150,000 sq. ft. FDA-compliant cGMP facility in Florham Park, New Jersey. The company develops and commercializes off-the-shelf allogeneic cell therapy candidates and biomaterial products derived from the postpartum placenta. Core cellular therapy products include CYNK-001 (placental NK cells), CYNK-101 (genetically-modified NK cells with high-affinity CD16), CyCART (allogeneic P CAR-T cells with TCR knockout), PDA-001/PDA-002 MLASCs (marketed under the brand name cenplacel-L for physician-directed investigational use), and placental exosomes (pEXO) in pre-clinical development. The advanced biomaterials franchise encompasses Interfyl®, Biovance®, Biovance® 3L, CentaFlex®, Biovance 3L Ocular, REBOUND™, NATALIN™, and Acelagraft™, with pipeline programs including Celularity Tendon Wrap (CTW), FUSE Bone Void Filler, and Celularity Placental Matrix (CPM). The Lifebank / LifebankUSA cellular banking platform (operating since 1998) and Celularity's CDMO services round out the portfolio. In 2026, Celularity out-licensed its commercial biomaterials portfolio to NexGel for up to $35 million, narrowing strategic focus onto longevity-oriented placental-derived cell therapies.

Product and service12 records
1Cenplacel-L (PDA-001/PDA-002 MLASCs)
CategoryLead cell therapy asset
Description

Proprietary formulation of Celularity's placental-derived allogeneic cell therapy (also referenced as PDA-001/PDA-002) positioned as the company's lead asset for physician-directed investigational use. Targets inflammation, degeneration and age-related disease, leveraging demonstrated immunomodulatory and regenerative properties of placental-derived mesenchymal-like adherent stromal cells.

2CYNK-001
CategoryCore cell therapy candidate
Description

Cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell therapy derived from placental hematopoietic stem cells. Demonstrates perforin/granzyme B expression, cytolytic activity against hematological and solid tumor lines, IFN-γ secretion, and expression of NKG2D, CD94, DNAM1, NKp30, NKp44 and NKp46. In clinical development for acute myeloid leukemia, glioblastoma multiforme, multiple myeloma, and COVID-19.

3CYNK-101
CategoryCore cell therapy candidate
Description

Genetically-modified placental NK cells engineered to express a high-affinity cleavage-resistant CD16 Fc receptor to augment antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibody therapeutics. FDA IND clearance obtained for glioblastoma multiforme.

4CyCART (Placental-derived CAR-T)
CategoryCore cell therapy candidate
Description

Allogeneic cryopreserved chimeric antigen receptor T cell therapy derived from postpartum placental T cells, engineered with CAR expression and knockout of endogenous T cell receptors (P CAR-T). Targets hematologic and solid tumor indications.

5Placental Exosomes (pEXO)
CategoryPreclinical cell-derived therapeutic modality
Description

Off-the-shelf extracellular vesicles isolated from postpartum human placenta, expressing characteristic markers CD9, CD63 and CD81. Contain over a thousand proteins and microRNAs evaluated at pre-clinical stage for regenerative and age-related disease applications.

6Biovance / Biovance 3L / Biovance 3L Ocular
CategoryAdvanced biomaterial product
Description

Human amniotic membrane allograft (Biovance), tri-layer human amniotic membrane allograft (Biovance 3L) and tri-layer amniotic membrane formulation for ocular surface reconstruction (Biovance 3L Ocular) used in wound care and ophthalmic applications.

7Interfyl
CategoryAdvanced biomaterial product
Description

Human connective tissue matrix derived from placenta for soft tissue management; commercial-stage regenerative biomaterial product.

8CentaFlex
CategoryAdvanced biomaterial product
Description

Human placenta tissue matrix commercial product for advanced regenerative applications.

9NATALIN / Acelagraft
CategoryAdvanced biomaterial product
Description

Tri-layer amniotic membrane allograft (NATALIN) and wound care product (Acelagraft) derived from placenta, both receiving FDA Tissue Reference Group recommendation letters.

10REBOUND
CategoryAdvanced biomaterial product
Description

Placental-derived allograft acquired from Sequence LifeScience, Inc., expanding the commercial biomaterials portfolio.

11Lifebank (LifebankUSA) Cellular Banking
CategoryCellular banking platform
Description

Private client biobanking service offering cryopreservation of placenta and umbilical cord blood and tissue for expectant parents and adults, with on-site vapor-phase liquid-nitrogen storage monitored 24/7/365 and proprietary procurement systems.

12Celularity IMPACT Manufacturing & CDMO Services
CategoryManufacturing platform / CDMO services
Description

Contract Development and Manufacturing Organization (CDMO) services delivered through Celularity's integrated GMP manufacturing platform (Celularity IMPACT) at the 150,000 sq ft FDA-compliant Florham Park, NJ facility, supporting cell therapy and biomaterial production for external partners.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MiMedx develops and commercializes placental-derived amniotic membrane and collagen-based regenerative products for wound care, orthopedics and surgical applications — directly comparable to Celularity's Biovance/Interfyl/CentaFlex/Natalin portfolio that was recently out-licensed to NexGel.

TypeBroad incumbent
Description

Organogenesis is a leading commercial-stage regenerative medicine company selling skin substitutes and wound care biologics (Apligraf, Dermagraft, PuraPly). It competes head-to-head with Celularity's biomaterials franchise in the same physician channels and CMS reimbursement framework.

TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf allogeneic iPSC-derived NK and T-cell therapies (e.g., FT516, FT596) for oncology — directly comparable to Celularity's CYNK-001, CYNK-101 and CyCART allogeneic placental-derived cell therapy programs.

TypeDirect peer
Description

Nkarta is a clinical-stage allogeneic NK cell therapy company targeting hematologic malignancies and autoimmune disease, providing a directly comparable allogeneic, off-the-shelf NK cell platform against Celularity's CYNK-001 and CYNK-101 programs.

5Pluristem Therapeutics
TypeDirect peer
Description

Pluristem develops placental-derived allogeneic mesenchymal-like stromal cell therapies (PLX cells) for regenerative medicine indications. Its cell source and manufacturing approach closely mirror Celularity's PDA-001/PDA-002 MLASC platform.

TypeDirect peer
Description

Mesoblast commercializes and develops allogeneic mesenchymal stromal cell therapies (Remestemcel-L, Rexlemestrocel-L) for inflammatory and degenerative diseases — directly comparable to Celularity's PDA-002 program in Crohn's disease, rheumatoid arthritis and diabetic foot ulcers.

TypeBroad incumbent
Description

Integra LifeSciences is a diversified regenerative medicine and surgical specialty company with skin substitutes, wound matrices and regenerative technologies (Integra Dermal Regeneration Template, AmnioExcel) overlapping Celularity's biomaterial wound care portfolio.

TypeDirect peer
Description

Century Therapeutics develops allogeneic iPSC-derived NK and T-cell therapies (including CAR-T) for oncology — directly comparable to Celularity's CyCART allogeneic placental CAR-T with TCR knockout platform.

TypeDirect peer
Description

Cryo-Cell is a direct competitor in private family cellular banking with a comparable cord blood and cord tissue cryopreservation subscription business, operating in the same U.S. consumer market as Celularity's Lifebank subsidiary.

10Athersys
TypeEmerging player
Description

Athersys is a clinical-stage cell therapy company developing MultiStem, an allogeneic cell therapy for inflammatory, neurological and regenerative indications — comparable in modality and target indications to Celularity's MLASC and regenerative medicine pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celularity

Regenerative Cell Therapycelularity.com

Celularity Inc. is a clinical-stage regenerative medicine company developing off-the-shelf placental-derived allogeneic cell therapies (cenplacel-L, CYNK-001, CYNK-101, CyCART) and operating the Lifebank cellular banking subscription service, targeting age-related and degenerative diseases through its Florham Park, NJ cGMP manufacturing platform.

What Celularity does

Celularity Inc. (NASDAQ: CELU) is a clinical-stage regenerative and cellular medicine company developing and commercializing off-the-shelf, cryopreserved, allogeneic cell therapies and advanced biomaterial products derived from the postpartum placenta, targeting age-related and degenerative diseases. Its core scientific platform, the Celularity IMPACT™ (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) system, operates from a 150,000 sq ft FDA-compliant cGMP facility in Florham Park, NJ, with nine Grade C/ISO-7 suites, six Grade D/ISO-8 labs, and 100+ specialized scientists. The pipeline includes placental-derived natural killer cell therapies (CYNK-001 and genetically-modified CYNK-101 with IND clearance for glioblastoma), allogeneic placental CAR-T cells with TCR knockout (CyCART), mesenchymal-like adherent stromal cells (PDA-001/PDA-002, marketed as cenplacel-L for physician-directed investigational use in Florida), and preclinical placental exosomes (pEXO); the wholly-owned Lifebank/LifebankUSA subsidiary provides private cellular banking subscription services for cord blood, cord tissue, and placental tissue.

Celularity's revenue model historically combined direct sales of biomaterial products (Biovance, Interfyl, CentaFlex, REBOUND, NATALIN, Biovance 3L Ocular) to wound care and orthopedic specialists, Lifebank subscription services, and CDMO offerings, with the biomaterials franchise out-licensed to NexGel in April 2026 for $13.3M upfront and up to $20.0M in milestones/royalties, leaving Celularity with exclusive manufacturing revenue from NexGel plus cenplacel-L commercialization via Fountain Life in Florida under Florida Statutes §458.3245 and §459.0127. Go-to-market motions are multi-pronged: enterprise field sales for physician access, channel partnerships for state-level investigational use, direct-to-consumer for Lifebank banking subscriptions, and OEM/licensing for the biomaterials franchise now handled by NexGel. Founded in 2017 as a spin-out from Celgene (tracing back to Anthrogenesis founded in 1998), Celularity became publicly traded on NASDAQ in 2021 and is led by Founder/Chairperson/CEO Robert J. Hariri, M.D., Ph.D., with recent additions including CCO Rick Gonzalez (May 2026) and Acting CFO John Sprague (February 2026).

Celularity firmographics

Firmographics
Name
Celularity
Legal name
Celularity Inc.
Website
https://celularity.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Celularity Inc. is a clinical-stage regenerative medicine company developing off-the-shelf placental-derived allogeneic cell therapies (cenplacel-L, CYNK-001, CYNK-101, CyCART) and operating the Lifebank cellular banking subscription service, targeting age-related and degenerative diseases through its Florham Park, NJ cGMP manufacturing platform.
Ownership category
akta.pro rank

Celularity industry classification

Industry
Product category
Regenerative Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAGAMAE
Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Regenerative medicine
  • Allogeneic cell therapy
  • Placental-derived biologics
  • Cellular medicine manufacturing
  • Cord tissue banking

Where Celularity is headquartered

Location

Headquarters

HQ city
Florham Park
HQ country
United States
HQ region
North America

Markets served

Celularity business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Advanced biomaterial product sales: Commercial sales of placental-derived biomaterial products including Biovance, Biovance 3L, Interfyl, CentaFlex, Natalin, REBOUND and Biovance 3L Ocular used in wound care, orthopedics, ocular surface reconstruction and surgical tendon management. Portfolio largely out-licensed to NexGel as of April 2026 with milestone payments and royalties, and Celularity retained exclusive manufacturing rights at its Florham Park facility.
  2. Cenplacel-L cell therapy sales: Commercial sales of cenplacel-L (placental-derived allogeneic investigational cell therapy, also known as PDA-001/PDA-002) to licensed physicians in permissive regulatory markets starting in Florida under Florida Statutes § 458.3245 and § 459.0127, via Fountain Life channel; therapy has not received FDA approval for any indication.
  3. Lifebank cellular banking subscription services: Private cellular banking subscription services for expectant parents and adults banking cord tissue, placental tissue and other cellular material via LifebankUSA platform; recurring consumer subscription revenue with over 20 years of operating history under predecessor brand.
  4. Contract Development and Manufacturing Organization (CDMO) services: CDMO services for strategic partners using Celularity's integrated GMP manufacturing platform, supporting both internal programs and external customers in cell therapy and biomaterial production.
  5. Licensing royalties and milestone payments (NexGel transaction): Up to $20.0 million in future milestone payments based on net sales thresholds and royalties on net sales of certain development-stage products licensed to NexGel as part of biomaterials portfolio transaction closed April 21, 2026.
  6. Exclusive manufacturing revenue from NexGel: Ongoing manufacturing revenue stream from acting as exclusive manufacturer for NexGel-licensed biomaterial products at FDA-compliant Florham Park, NJ facility.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualLifebank private cellular banking subscription for expectant parents and adults

Go-to-market motion6 records

Celularity product offering

Product offering

Core offering

Celularity develops and commercializes off-the-shelf, allogeneic, cryopreserved cell therapies and advanced biomaterial products derived from postpartum human placenta, including placental Natural Killer cell therapies (CYNK-001, CYNK-101), placental CAR-T cells (CyCART), placental mesenchymal-like adherent stromal cells (PDA-001/PDA-002 / cenplacel-L) and placental exosomes. The company also sells advanced biomaterial allografts (Biovance, Interfyl, CentaFlex, NATALIN, REBOUND, Acelagraft) and operates the LifebankUSA private cellular banking subscription service, with manufacturing performed at a 150,000 sq ft FDA-registered cGMP facility in Florham Park, NJ.

Product overview

Celularity operates a platform-plus-modules architecture anchored by its Celularity IMPACT™ fully integrated placental-derived cell therapy manufacturing platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) located at a 150,000 sq. ft. FDA-compliant cGMP facility in Florham Park, New Jersey. The company develops and commercializes off-the-shelf allogeneic cell therapy candidates and biomaterial products derived from the postpartum placenta. Core cellular therapy products include CYNK-001 (placental NK cells), CYNK-101 (genetically-modified NK cells with high-affinity CD16), CyCART (allogeneic P CAR-T cells with TCR knockout), PDA-001/PDA-002 MLASCs (marketed under the brand name cenplacel-L for physician-directed investigational use), and placental exosomes (pEXO) in pre-clinical development. The advanced biomaterials franchise encompasses Interfyl®, Biovance®, Biovance® 3L, CentaFlex®, Biovance 3L Ocular, REBOUND™, NATALIN™, and Acelagraft™, with pipeline programs including Celularity Tendon Wrap (CTW), FUSE Bone Void Filler, and Celularity Placental Matrix (CPM). The Lifebank / LifebankUSA cellular banking platform (operating since 1998) and Celularity's CDMO services round out the portfolio. In 2026, Celularity out-licensed its commercial biomaterials portfolio to NexGel for up to $35 million, narrowing strategic focus onto longevity-oriented placental-derived cell therapies.

Differentiator

Problem solved

Functional benefit

Brands

  • Lifebank (LifebankUSA): Private cellular and tissue biobanking service offering cord blood, cord tissue, and placental tissue preservation for families, operating since 1998.
  • CYNK-001
  • CYNK-101
  • CyCART
  • PDA-001 / PDA-002
  • Cenplacel-L
  • Biovance
  • Biovance 3L
  • Interfyl
  • CentaFlex
  • NATALIN
  • REBOUND
  • Celularity IMPACT

Products and services

  • Cenplacel-L (PDA-001/PDA-002 MLASCs) Proprietary formulation of Celularity's placental-derived allogeneic cell therapy (also referenced as PDA-001/PDA-002) positioned as the company's lead asset for physician-directed investigational use. Targets inflammation, degeneration and age-related disease, leveraging demonstrated immunomodulatory and regenerative properties of placental-derived mesenchymal-like adherent stromal cells.
  • CYNK-001 Cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell therapy derived from placental hematopoietic stem cells. Demonstrates perforin/granzyme B expression, cytolytic activity against hematological and solid tumor lines, IFN-γ secretion, and expression of NKG2D, CD94, DNAM1, NKp30, NKp44 and NKp46. In clinical development for acute myeloid leukemia, glioblastoma multiforme, multiple myeloma, and COVID-19.
  • CYNK-101 Genetically-modified placental NK cells engineered to express a high-affinity cleavage-resistant CD16 Fc receptor to augment antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibody therapeutics. FDA IND clearance obtained for glioblastoma multiforme.
  • CyCART (Placental-derived CAR-T) Allogeneic cryopreserved chimeric antigen receptor T cell therapy derived from postpartum placental T cells, engineered with CAR expression and knockout of endogenous T cell receptors (P CAR-T). Targets hematologic and solid tumor indications.
  • Placental Exosomes (pEXO) Off-the-shelf extracellular vesicles isolated from postpartum human placenta, expressing characteristic markers CD9, CD63 and CD81. Contain over a thousand proteins and microRNAs evaluated at pre-clinical stage for regenerative and age-related disease applications.
  • Biovance / Biovance 3L / Biovance 3L Ocular Human amniotic membrane allograft (Biovance), tri-layer human amniotic membrane allograft (Biovance 3L) and tri-layer amniotic membrane formulation for ocular surface reconstruction (Biovance 3L Ocular) used in wound care and ophthalmic applications.
  • Interfyl Human connective tissue matrix derived from placenta for soft tissue management; commercial-stage regenerative biomaterial product.
  • CentaFlex Human placenta tissue matrix commercial product for advanced regenerative applications.
  • NATALIN / Acelagraft Tri-layer amniotic membrane allograft (NATALIN) and wound care product (Acelagraft) derived from placenta, both receiving FDA Tissue Reference Group recommendation letters.
  • REBOUND Placental-derived allograft acquired from Sequence LifeScience, Inc., expanding the commercial biomaterials portfolio.
  • Lifebank (LifebankUSA) Cellular Banking Private client biobanking service offering cryopreservation of placenta and umbilical cord blood and tissue for expectant parents and adults, with on-site vapor-phase liquid-nitrogen storage monitored 24/7/365 and proprietary procurement systems.
  • Celularity IMPACT Manufacturing & CDMO Services Contract Development and Manufacturing Organization (CDMO) services delivered through Celularity's integrated GMP manufacturing platform (Celularity IMPACT) at the 150,000 sq ft FDA-compliant Florham Park, NJ facility, supporting cell therapy and biomaterial production for external partners.

Companies that use Celularity

Customer profile

Ideal customer profiles4 records

Celularity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Celularity partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights6 records

Celularity competitors and assessment

Company assessment

Direct peers

  • MiMedx Group: MiMedx develops and commercializes placental-derived amniotic membrane and collagen-based regenerative products for wound care, orthopedics and surgical applications — directly comparable to Celularity's Biovance/Interfyl/CentaFlex/Natalin portfolio that was recently out-licensed to NexGel.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf allogeneic iPSC-derived NK and T-cell therapies (e.g., FT516, FT596) for oncology — directly comparable to Celularity's CYNK-001, CYNK-101 and CyCART allogeneic placental-derived cell therapy programs.
  • Nkarta: Nkarta is a clinical-stage allogeneic NK cell therapy company targeting hematologic malignancies and autoimmune disease, providing a directly comparable allogeneic, off-the-shelf NK cell platform against Celularity's CYNK-001 and CYNK-101 programs.
  • Pluristem Therapeutics: Pluristem develops placental-derived allogeneic mesenchymal-like stromal cell therapies (PLX cells) for regenerative medicine indications. Its cell source and manufacturing approach closely mirror Celularity's PDA-001/PDA-002 MLASC platform.
  • Mesoblast: Mesoblast commercializes and develops allogeneic mesenchymal stromal cell therapies (Remestemcel-L, Rexlemestrocel-L) for inflammatory and degenerative diseases — directly comparable to Celularity's PDA-002 program in Crohn's disease, rheumatoid arthritis and diabetic foot ulcers.
  • Century Therapeutics: Century Therapeutics develops allogeneic iPSC-derived NK and T-cell therapies (including CAR-T) for oncology — directly comparable to Celularity's CyCART allogeneic placental CAR-T with TCR knockout platform.
  • Cryo-Cell International: Cryo-Cell is a direct competitor in private family cellular banking with a comparable cord blood and cord tissue cryopreservation subscription business, operating in the same U.S. consumer market as Celularity's Lifebank subsidiary.

Broad incumbents

  • Organogenesis Holdings: Organogenesis is a leading commercial-stage regenerative medicine company selling skin substitutes and wound care biologics (Apligraf, Dermagraft, PuraPly). It competes head-to-head with Celularity's biomaterials franchise in the same physician channels and CMS reimbursement framework.
  • Integra LifeSciences: Integra LifeSciences is a diversified regenerative medicine and surgical specialty company with skin substitutes, wound matrices and regenerative technologies (Integra Dermal Regeneration Template, AmnioExcel) overlapping Celularity's biomaterial wound care portfolio.

Emerging players

  • Athersys: Athersys is a clinical-stage cell therapy company developing MultiStem, an allogeneic cell therapy for inflammatory, neurological and regenerative indications — comparable in modality and target indications to Celularity's MLASC and regenerative medicine pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Celularity social profiles

Digital presence

Celularity compliance and trust

Trust signal

Compliance4 records

Celularity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celularity leadership team

Management profile

Number of profiles

Profiles14 records

Celularity subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Celularity funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celularity M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celularity

What does Celularity do?

Celularity develops and commercializes off-the-shelf, allogeneic, cryopreserved cell therapies and advanced biomaterial products derived from postpartum human placenta, including placental Natural Killer cell therapies (CYNK-001, CYNK-101), placental CAR-T cells (CyCART), placental mesenchymal-like adherent stromal cells (PDA-001/PDA-002 / cenplacel-L) and placental exosomes. The company also sells advanced biomaterial allografts (Biovance, Interfyl, CentaFlex, NATALIN, REBOUND, Acelagraft) and operates the LifebankUSA private cellular banking subscription service, with manufacturing performed at a 150,000 sq ft FDA-registered cGMP facility in Florham Park, NJ.

Is Celularity a public or private company?

Celularity is a public company. It is classified as public and is currently operating.

When was Celularity founded?

Celularity was founded in 2017. It employs 101 to 250 people.

Where is Celularity based?

Celularity is headquartered in Florham Park, United States, in the North America region.

How does Celularity make money?

Six revenue lines are on record. Advanced biomaterial product sales are the primary driver. The others are cenplacel-L cell therapy sales, lifebank cellular banking subscription services, contract Development and Manufacturing Organization (CDMO) services, licensing royalties and milestone payments (NexGel transaction) and exclusive manufacturing revenue from NexGel.

Who are Celularity's main competitors?

Direct peers on record are MiMedx Group, Fate Therapeutics, Nkarta, Pluristem Therapeutics, Mesoblast, Century Therapeutics and Cryo-Cell International. Broad incumbents are Organogenesis Holdings and Integra LifeSciences. Athersys is listed as an emerging player.

Does Celularity have an API?

No public API is recorded for Celularity.

What industry is Celularity in?

Celularity's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic), with a secondary code of HLAGAMAE, Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsHead-To-Head Review: Celularity (NASDAQ:CELU) versus Upstream Bio (NASDAQ:UPB)A head-to-head review compares Celularity and Upstream Bio on profitability, ownership, analyst ratings, and valuation. Upstream Bio has a stronger consensus rating and higher upside, while Celularity has higher revenue and earnings. The review concludes Celularity beats Upstream Bio on 7 of 13 factors.American Banking and Market NewsFinancial Analysis: Scinai Immunotherapeutics (NASDAQ:SCNI) vs. Celularity (NASDAQ:CELU)A comparison of Celularity and Scinai Immunotherapeutics shows Scinai beats on seven of ten factors, including higher institutional ownership (58.4% vs 19.0%) and lower volatility (beta 2.13 vs 0.88). Celularity has higher revenue ($26.55M vs $1.49M) but both report net losses, with Celularity trading at a lower price-to-earnings ratio.TradingViewCelularity Signs Exclusive U.S. Peptide API Manufacturing Collaboration with VesaliusCelularity signed an exclusive collaboration with Vesalius to purify, process, test, and manufacture Peptual-branded peptide APIs at its New Jersey facility. The deal uses supplier-provided bulk peptide material and aims for cGMP processes, but commercial supply to U.S. compounding pharmacies is uncertain and not authorized by the agreement alone.Markets DailyCelularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 52.3% in SeptemberCelularity's short interest fell 52.3% to 391,276 shares as of September 30, with 1.6% of shares short sold. Weiss Ratings raised the stock from a sell (e+) to a sell (d-) rating, and the stock traded down 7.7% to $1.31. The company reported $0.02 EPS and $3.85 million revenue for the quarter.American Banking and Market NewsCelularity, Inc. (NASDAQ:CELU) Stock Short Interest Drops 56.7%Celularity's short interest fell 56.7% to 821,020 shares as of September 15th, down from 1.897 million on August 31st. Weiss Ratings upgraded the stock from a sell (e+) to a sell (d-) rating, and institutional investor C V Starr & Co. acquired a new stake.BioSpaceCelularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating ImprovementsCelularity closed an initial financing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants. The closing is part of a recapitalization plan up to $28 million, including restructuring of $3 million in existing debt. The company expects positive monthly operating cash flow by the end of Q1 2027.Markets DailyDyadic International (NASDAQ:DYAI) & Celularity (NASDAQ:CELU) Head-To-Head ComparisonDyadic International and Celularity are compared on valuation, institutional ownership, earnings, and analyst ratings. Dyadic beats Celularity on 10 of 14 factors, with a consensus price target of $3.00 implying 622.89% upside. Dyadic is deemed more favorable by analysts.Longevity.TechnologyCelularity lands $300m MuseCell manufacturing dealCelularity and Singapore's MuseCell Innovations announced a manufacturing deal for Dezawa MuseCells at Celularity's Florham Park, New Jersey facility. The initial phase covers perinatal sources and two related products, with projected $300 million in purchases and 200 jobs over five years.Longevity.TechnologyCelularity, MuseCell Innovations to build US Dezawa MuseCell plantCelularity and MuseCell Innovations agreed to build a U.S. Dezawa MuseCell manufacturing plant at Celularity's Florham Park, New Jersey facility. Initial production will include DMCs and DMC-derived products, with estimates of over $300 million in purchases and 200 jobs over five years.NJBIZCelularity deal could bring $300M, 200 jobs to NJCelularity Inc. of Florham Park, New Jersey, announced on Aug. 27 a manufacturing collaboration with Singapore-based MuseCell Innovations to produce Dezawa MuseCells at its 147,215-square-foot facility. The deal could generate more than $300 million in purchases over five years and over 200 high-tech jobs. Expansion beyond the initial project is possible.